U.S. Food and Drug Administration Accepts for Priority Review Deciphera’s New Drug Application for Vimseltinib for the Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT)

KalVista Announces FDA Acceptance of New Drug Application for Sebetralstat for Oral On-Demand Treatment of Hereditary Angioedema

drugs.com - 03/Sep 20:09

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--Sep. 3, 2024-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the U.S....

U.S. lawmakers call out FDA for slow ‘smoke-free’ product review amid growing illegal market

westernstandardonline.com - 13/Sep 17:50

U.S. lawmakers and health groups are upset about how the Food and Drug Administration (FDA) is handling e-cigarettes and other smoke-free products.

U.S. lawmakers call out FDA for slow ‘smoke-free’ product review amid growing illegal market

westernstandardonline.com - 13/Sep 17:50

U.S. lawmakers and health groups are upset about how the Food and Drug Administration (FDA) is handling e-cigarettes and other smoke-free products.

KalVista announces FDA acceptance of NDA for sebetralstat for oral on-demand treatment of HAE

haei.org - 03/Sep 17:29

KalVista announces FDA acceptance of New Drug Application for sebetralstat for oral on-demand treatment of hereditary angioedema KalVista...

Tremfya (guselkumab) Receives U.S. FDA Approval for Adults with Moderately to Severely Active Ulcerative Colitis

drugs.com - 13/Sep 07:09

HORSHAM, Pa. (September 11, 2024) – Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved...

Tremfya (guselkumab) Receives U.S. FDA Approval for Adults with Moderately to Severely Active Ulcerative Colitis

drugs.com - 13/Sep 07:09

HORSHAM, Pa. (September 11, 2024) – Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved...

FDA Approves Ebglyss (lebrikizumab-lbkz) for the Treatment of Atopic Dermatitis

drugs.com - 13/Sep 00:09

INDIANAPOLIS, Sept. 13, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today the U.S. Food and Drug Administration (FDA) approved...

Most Tobacco Instagram Posts Do Not Adhere to FDA Warning Requirements

drugs.com - 16:09

MONDAY, Sept. 16, 2024 -- Most nicotine brand Instagram posts do not adhere to U.S. Food and Drug Administration (FDA) health warning requirements for...

FDA Approves Tremfya for Ulcerative Colitis

drugs.com - 22:24

MONDAY, Sept. 16, 2024 -- The U.S. Food and Drug Administration has approved Tremfya (guselkumab) for the treatment of adults with moderately to...

FDA Approves Tremfya for Ulcerative Colitis

drugs.com - 22:24

MONDAY, Sept. 16, 2024 -- The U.S. Food and Drug Administration has approved Tremfya (guselkumab) for the treatment of adults with moderately to...

Rubriques :

U.S. Food and Drug Administration Accepts for Priority Review Deciphera’s New Drug Application for Vimseltinib for the Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT)

Articles similaires

KalVista Announces FDA Acceptance of New Drug Application for Sebetralstat for Oral On-Demand Treatment of Hereditary Angioedema

U.S. lawmakers call out FDA for slow ‘smoke-free’ product review amid growing illegal market

U.S. lawmakers call out FDA for slow ‘smoke-free’ product review amid growing illegal market

KalVista announces FDA acceptance of NDA for sebetralstat for oral on-demand treatment of HAE

Tremfya (guselkumab) Receives U.S. FDA Approval for Adults with Moderately to Severely Active Ulcerative Colitis

Tremfya (guselkumab) Receives U.S. FDA Approval for Adults with Moderately to Severely Active Ulcerative Colitis

FDA Approves Ebglyss (lebrikizumab-lbkz) for the Treatment of Atopic Dermatitis

Most Tobacco Instagram Posts Do Not Adhere to FDA Warning Requirements

FDA Approves Tremfya for Ulcerative Colitis

FDA Approves Tremfya for Ulcerative Colitis

Les derniers communiqués